ZOM — Zomedica Income Statement
0.000.00%
Last trade - 00:00
- $132.29m
- $41.80m
- $25.19m
- 35
- 40
- 31
- 27
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 4.13 | 18.9 | 25.2 |
Cost of Revenue | |||||
Gross Profit | — | — | 3.05 | 13.7 | 17.3 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 19.8 | 16.8 | 25 | 40.9 | 68.5 |
Operating Profit | -19.8 | -16.8 | -20.8 | -21.9 | -43.3 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -19.8 | -16.9 | -20.7 | -19.4 | -35.9 |
Provision for Income Taxes | |||||
Net Income After Taxes | -19.8 | -16.9 | -18.4 | -17 | -34.5 |
Net Income Before Extraordinary Items | |||||
Net Income | -19.8 | -16.9 | -18.4 | -17 | -34.5 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -19.8 | -16.9 | -18.4 | -17 | -34.5 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.186 | -0.046 | -0.019 | -0.017 | -0.028 |